

Based on the "Stock Detailed Analysis Report" for SUNPHARMA.NS generated on 2026-01-03, here is the positional trading analysis.

Step 1: Audit the Data

- * **Data Present:**
 - * Daily Price Action (3-Year and 1-Year views).
 - * Moving Averages (EMA 20, 50, 200) and Crossover status.
 - * Relative Strength (RS) against the sector and index.
 - * Momentum Indicators (RSI, MACD).
 - * Volatility Indicators (Bollinger Bands, ATR, Squeeze).
 - * Trend Indicators (Supertrend).
 - * Fundamental Snapshots (Revenue, EPS, Valuation).
- * **Data Missing:**
 - * Weekly/Monthly specific charts (though inferred from long-term daily charts).
 - * Detailed Volume Profile or Delivery data (though basic Volume MA is present).
- * **Confidence Level: High.**
 - * The report is comprehensive and covers trend, momentum, volatility, and fundamentals.
 - * **Note:** The report date is January 3, 2026. This analysis treats the data as current to that simulated date.*

Step 2: Analyze the Setup

- * **Price Structure & Trend:**
 - * **Long-Term:** **Bullish**. The price (1728) is above the 200 EMA (1705), indicating the primary trend is still upward.
 - * **Intermediate-Term:** **Corrective/Bearish**. The price is trading below the EMA 20 (1747) and EMA 50 (1741). The Supertrend (Page 10) generated a Sell signal on Dec 18, 2025.
 - * **Pattern:** The stock is experiencing a pullback from highs of ~1900. It is currently sandwiched between overhead resistance (EMA 20/50) and major support (EMA 200).
- * **Momentum & Confluence:**
 - * **Bearish Momentum:** MACD is negative and below the signal line (Page 12). RSI is at 42 (Page 16), which is weak but not yet oversold (<30).
 - * **Support Zone:** The 200 EMA is at **1705**. The Lower Bollinger Band is at **1693**. This creates a strong "confluence zone" of support between 1690-1705.
 - * **Relative Strength:** The stock is lagging. The RS Score is 48.4 (Neutral) and the RS line is trending down, indicating it is underperforming the Pharma index in the short term.
- * **Verdict:** The stock is in a "No Trade Zone." It is falling towards major support but has not shown signs of stabilization or reversal yet. Buying now is "catching a falling knife" before the floor (200 EMA) is tested.

Step 3: Formulate the Recommendation

Recommendation: NO

Do not enter at the current market price (1728.00). The short-term trend is down, and momentum is negative. You should wait for the price to test the 200 EMA support and show a reversal, OR reclaim the short-term moving averages.

Conditional Plan (Watchlist):

Since the long-term trend is up, this is a high-probability "dip buy" setup *if* specific conditions are met.

* **Condition to Buy:**

- * **Aggressive:** A daily candle touching the **1700-1710** zone (200 EMA) followed by a bullish candlestick pattern (e.g., Hammer or Green Engulfing).

* **Conservative (Preferred):** A daily Close above the **EMA 20 (approx. 1750)**. This confirms the short-term correction is over and momentum has shifted back to the upside.

* **Entry Price:** **INR 1755** (Buy Stop order just above the EMA 20/50 cluster to confirm strength).

* **Stop Loss:** **INR 1685** (Daily close basis).

* **Rationale:** This is below the critical 200 EMA (1705) and the Lower Bollinger Band (1693). If this level breaks, the long-term trend is violated.

* **Take Profit:** **INR 1920 - INR 1950**

* **Rationale:** Re-test of the recent swing highs (~1920) and the Analyst Target Price (1951).

* **Risk/Reward:** Approx 1:2.4 (Risking ~4% to make ~9.5%).

Summary: The stock is fundamentally strong but technically weak in the short term. Patience is required to let it find support at the 200 EMA (1705) before initiating a long position.

News & Analyst Targets

As a stock research analyst, I have gathered the latest information on **Sun Pharmaceutical Industries Ltd. (SUNPHARMA)** for the week ending **January 3, 2026**.

1) Latest News for SUNPHARMA (This Week)

* **Trading Window Closure:** Effective **January 1, 2026**, Sun Pharma has closed its trading window for insiders. This is a routine compliance measure ahead of the declaration of its Q3 FY26 financial results. The window will remain closed until 48 hours after the results are announced.

* **Leqselvi Launch Delays:** Reports highlight that while Sun Pharma received US FDA approval for its alopecia drug **Leqselvi (deuruxolitinib)**, the commercial launch remains indefinitely delayed due to ongoing patent litigation. This continues to be a key point of discussion for investors monitoring the company's US specialty portfolio.

* **Ilumya Launch in India:** The company recently announced the launch of **Ilumya (tildrakizumab)** in India. This drug, used for treating moderate-to-severe plaque psoriasis, has been a key driver in its global specialty business and is now available for the domestic market.

* **Stock Price Volatility:** The stock has seen mixed trading sessions this week (trading around **INR 1,720 - INR 1,730** levels), reacting to broader market trends and digesting recent regulatory updates regarding its manufacturing facilities.

2) Brokerage Upgrades & Downgrades

* **Choice Equity Broking (Fresh Recommendation):** On **December 30, 2025**, Choice Equity recommended a **BUY** rating on Sun Pharma with a target price of **INR 1,825**, citing a potential upside of approximately 6% from the trading price at that time.

* **MarketsMojo (Downgrade):** In mid-December, the research platform adjusted its rating from "Strong Buy" to **"Buy"**, reflecting a slightly more cautious but still positive stance due to recent sector headwinds.

* **Jefferies & Nuvama (Maintained):** Major foreign brokerages have largely maintained their stance from late 2025. **Jefferies** remains bullish (Buy) with a high target, while **Nuvama** has maintained a cautious "Hold" rating, citing valuation and execution risks.

3) Other News Impacting SUNPHARMA

* **US FDA 'OAI' Classification (Negative Impact):** In mid-December, the US FDA classified Sun Pharma's **Baska manufacturing facility** as **"Official Action Indicated" (OAI)**. This classification implies that the FDA found objectionable conditions that require regulatory or administrative action. This outcome typically delays product approvals from the specific site until the issues are resolved.

* **Semaglutide Legal Ruling (Mixed Impact):** In a significant legal development late last month, the **Delhi High Court** permitted Sun Pharma to **manufacture and export** its generic version of the popular weight-loss drug **Semaglutide**. However, the court **barred domestic sales** in India until the expiry of Novo Nordisk's patent in **March 2026**. This is seen as a partial win, allowing the company to tap into export markets immediately while preparing for a domestic launch later.

4) Analyst Targets for SUNPHARMA

The following table summarizes the latest price targets from major brokerage firms and the analyst community. The stock is currently trading near **INR 1,720**.

Brokerage / Firm	Rating	Target Price (INR)	Sentiment
JM Financial	BUY	2,115	Bullish
Jefferies	BUY	2,070	Bullish
Consensus Average	BUY	1,950	Positive
ICICI Securities	BUY	1,895	Positive
Nuvama	HOLD	1,830	Cautious
Choice Equity	BUY	1,825	Positive
Motilal Oswal	BUY	1,800	Moderate

Target based on previous quarter notes; retained in recent consolidations.

Analyst Summary: The consensus among the analyst community remains largely **positive**, with an average target price indicating an upside of roughly **10-13%** from current levels. The primary bullish thesis relies on the ramp-up of the specialty business (Ilumya, Winlevi), while the "Hold" ratings typically flag regulatory risks (FDA observations) and rich valuations.


Stock Detailed Analysis Report

SUNPHARMA.NS

Current Price: ₹1728.00

Generated: 2026-01-03 12:44

SUNPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	8.97%	10.64%
Net Income	Yes	No	14.12%	49.47%
ROE	Yes	No	0.61%	30.45%
EPS	Yes	No	14.29%	49.67%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	7.57%	2.54%
Net Income	No	5.99%	-4.31%
ROE	No	-32.32%	-32.32%
EPS	Yes	-4.72%	1.45%

SUNPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Neutral
RS Score:	48.4/100

:

== RS RATIOS ==:

1M RS:	0.955 [Neutral]
3M RS:	0.983 [Neutral]
6M RS:	0.997 [Neutral]
1Y RS:	0.911 [Neutral]

:

== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
--------------------	---------------------

:


SIGNAL CRITERIA::

✗ Emerging RS:	Not accelerating
✓ Medium-term Lagging:	6M=0.997, 1Y=0.911 (≤ 1.0)
✓ Performance Improving:	3M (+5.6%) > 6M (+3.0%)


Relative Strength Analysis: SUNPHARMA.NS vs ^CNXPHARMA

Classification: Neutral


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



SUNPHARMA.NS - EMA Crossover Summary

EMA 20:	1747.16
EMA 50:	1741.33
EMA 200:	1705.35
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-18 00:00:00
Golden Cross Price:	1758.80


SUNPHARMA.NS EMA Crossover Analysis



SUNPHARMA.NS - Bollinger Bands Summary

Current Price:	1728.00
Upper Band:	1820.79
Middle Band (SMA 20):	1757.29
Lower Band:	1693.80
%B:	0.2693
Band Width:	0.0723
Status:	Lower Half
Signal:	None
Recent Signal 1:	Sell Signal at 2025-12-01 00:00:00


SUNPHARMA.NS Bollinger Bands (20, 2) Analysis



SUNPHARMA.NS - Supertrend Summary

Status:	DOWNTREND (Sell)
Supertrend Value:	1788.19
Signal Identified On:	2025-12-18

Supertrend Analysis for SUNPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




SUNPHARMA.NS - MACD Summary

MACD Line:	-12.59
Signal Line:	-6.41
Histogram:	-6.19
Trend:	Bearish
Momentum:	Weakening
Signal:	None

SUNPHARMA.NS Price






SUNPHARMA.NS MACD (12, 26, 9)



SUNPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.0723
ATR:	22.5500
Total Signals:	23
Signal 1:	BB Squeeze at 2025-12-16 00:00:00 (Price: 1781.30)
Signal 2:	BB Squeeze at 2025-12-17 00:00:00 (Price: 1792.90)
Signal 3:	ATR Contraction at 2025-12-31 00:00:00 (Price: 1719.70)
Signal 4:	ATR Contraction at 2026-01-01 00:00:00 (Price: 1721.10)
Signal 5:	ATR Contraction at 2026-01-02 00:00:00 (Price: 1728.00)




SUNPHARMA.NS - Volatility Squeeze Analysis



SUNPHARMA.NS - RSI-Volume Summary

Current RSI:	42.06
Current Volume:	974123
Volume MA 20:	1798664
Bullish Divergences:	2
Bearish Divergences:	3
Bullish Div 1:	Date: 2024-01-17 00:00:00, Price: 1299.00
Bullish Div 2:	Date: 2025-06-04 00:00:00, Price: 1664.90
Bearish Div 1:	Date: 2024-04-01 00:00:00, Price: 1629.25
Bearish Div 2:	Date: 2025-07-30 00:00:00, Price: 1733.80

SUNPHARMA.NS RSI-Volume Divergence Analysis



Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Live Share Price Today, Share Analysis and Chart

1728.00 6.90 (0.40%)

 Watchlist
  Portfolio
  Alert
  My Notes
 [TRADE STOCK](#)

[Overview](#)
[FORECASTER](#)
[STOCK REPORT](#)
[Buy Sell Zone](#)
[F&O](#)
[Financials](#)
[News ▾](#)
[Reports](#)
[Technicals ▾](#)
[Shareholding ▾](#)
[Deals ▾](#)
[Corporate Actions ▾](#)
[Alerts](#)
[About](#)

Analyst Price Target  

1,951

1Yr Price target upside is 13%

Embed DVM



Right Now	1 Year Forward
Undervalued 25.5%	Undervalued 40.3%

INSIGHT Sun Pharmaceutical is undervalued at both current PE and future earnings estimates

ROE Ann. % [Above Industry Median](#)

15.1

Broker Average Target [11.19% upside](#)

1,921.38

Market Capitalization >
Market Leader

414,605.1

Price to Book [Above Industry Median](#)

- DVM
- Key Metrics
- Price Chart
- Forecaster
- Financials
- Technicals
- Shareholding
- Deals
- Documents
- Corporate actions
- Company Profile

Trendlyne Snapshot - SUNPHARMA_forecaster

MarketsSTARFOLIOAlertsF&OMFReportsScreenersSubscribeSuperstarsPortfolioWatchlistInsider TradesResultsData DownloaderMore

Search Stock, IPO, MF

IndiaA

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [SUN PHARMACEUTICAL INDUSTRIES LTD.](#)

Sun Pharmaceutical Industries Ltd. ⓘ

NSE: SUNPHARMA | BSE: 524715

Mid-range Performer ⓘ

In 10 Starfolio Baskets

1728.006.90 (0.40%)

1.0M NSE+BSE Volume

NSE 02 Jan, 2026 3:31 PM (IST)

WatchlistPortfolioAlertMy Notes

TRADE STOCK

OverviewFORECASTERSTOCK REPORTBuy Sell ZoneF&OFinancialsNewsReportsTechnicalsShareholdingDealsCorporate ActionsAlertsAbout

Sun Pharmaceutical - SUNPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 38 analysts

Sun Pharmaceutical has a share price target of Rs 1951, revenue growth forecast of 9.1%, and profit growth estimate of 2.7% for FY26, based on top 38 analyst calls.

Sun Pharmaceutical FORECASTER - Analyst Estimates ⓘ

[FORECASTER DASHBOARD →](#)

